Efficacy of high-dose chemotherapy and autologous stem cell transplant for recurrent Wilms' tumor: A meta-analysis

Journal of Pediatric Hematology/Oncology

Volumn 32, Issue 6, 2010, Pages 454-461

  Presson, Angela ^a,b   Moore, Theodore B ^b   Kempert, Pamela ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MATTEL CHILDREN S HOSPITAL   (United States)

Author keywords

Autologous stem cell transplant; High dose chemotherapy; Nephroblastoma; Relapse; Wilms' tumor

Indexed keywords

CARBOPLATIN; ETOPOSIDE; MELPHALAN; ANTINEOPLASTIC AGENT;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CARDIOMYOPATHY; CHEMOTHERAPY INDUCED EMESIS; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; EVENT FREE SURVIVAL; GASTROINTESTINAL HEMORRHAGE; GLOMERULAR DYSFUNCTION; HUMAN; KIDNEY FAILURE; LUNG TOXICITY; MEDLINE; MUCOSA INFLAMMATION; NEPHROBLASTOMA; OVERALL SURVIVAL; PERICARDIAL EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; SALVAGE THERAPY; SURVIVAL RATE; SYSTEMATIC REVIEW; TUBULAR DYSFUNCTION; TUMOR RECURRENCE; VEIN OCCLUSION; ADOLESCENT; CHILD; FEMALE; KAPLAN MEIER METHOD; KIDNEY TUMOR; MALE; META ANALYSIS; METHODOLOGY; MORTALITY; MULTIMODALITY CANCER THERAPY; PRESCHOOL CHILD; STEM CELL TRANSPLANTATION;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; KIDNEY NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; WILMS TUMOR;

EID: 77955865092     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181e001c2     Document Type: Article

References (29)

1. Campbell AD, Cohn S, Reynolds M, et al. Treatment of relapsed Wilms' tumor with high-dose therapy and autologous hematopoietic stem-cell rescue: the experience at Children's Memorial Hospital. J Clin Oncol. 2004;22:2885-2890.
2. Garaventa A, Hartmann O, Bernard JC, et al. Autologous bone marrow transplantation for pediatric Wilms' tumor: the experience of the European bone marrow transplantation solid tumor registry. Med Pediatr Oncol. 1994;22:11-14.
3. Kremens B, Gruhn B, Klingebiel T, et al. High-dose chemotherapy with autologous stem cell rescue in children with nephroblastoma. Bone Marrow Transplant. 2002;30: 893-898.
4. D'Angio GJ, Breslow N, Beckwith B, et al. Treatment of Wilms' tumor. Results of the Third National Wilms' Tumor Study. Cancer. 1989;64:349-360.
5. Green DM, Breslon N, Evans I, et al. Treatment of children with stage IV favorable histology Wilms tumor: a report from the National Wilms Tumor Study Group. Med Pediatr Oncol. 1996;26:147-152.
6. Green DM, Breslon N, Beckwith B, et al. Treatment with nephrectomy only for small, stage I/favorable histology Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol. 2001;19:3719-3724.
7. Pritchard J, Imeson J, Barnes J, et al. Results of the United Kingdom Children's Cancer Study Group first Wilms' Tumor Study. J Clin Oncol. 1995;13:124-133.
8. Mitchell C, Morris Jones P, Kelsey A, et al. The treatment of Wilms' tumour: results of the United Kingdom Children's cancer study group (UKCCSG) second Wilms' tumour study. Br J Cancer. 2000;83:602-608.
9. Tournade MF, Com-Nougue C, Varte PA, et al. Results of the Sixth International Society of Pediatric Oncology Wilms' Tumor Trial and Study: a risk-adapted therapeutic approach in Wilms' tumor. J Clin Oncol. 1993;11:1014-1023.
10. Graf N, Tournade MF, De Kraker J. The role of preoperative chemotherapy in the management of Wilms' tumor. The SIOP studies. International Society of Pediatric Oncology. Urol Clin North Am. 2000;27:443-454.
11. Tournade MF, Com-Nouge C, de Kraker J, et al. Optimal duration of preoperative therapy in unilateral and nonmeta-static Wilms' tumor in children older than 6 months: results of the Ninth International Society of Pediatric Oncology Wilms' Tumor Trial and Study. J Clin Oncol. 2001;19:488-500.
12. Grundy P, Breslow N, Green DM, et al. Prognostic factors for children with recurrent Wilms' tumor: results from the Second and Third National Wilms' Tumor Study. J Clin Oncol. 1989;7:638-647.
13. Lemerle J, Voute PA, Tournade MF, et al. Effectiveness of preoperative chemotherapy in Wilms' tumor: results of an International Society of Paediatric Oncology (SIOP) clinical trial. J Clin Oncol. 1983;1:604-609.
14. Nitschke R, Parkhurst J, Sullivan J, et al. Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study. J Pediatr Hematol Oncol. 1998;20:315-318.
15. Ceschel S, Casotto V, Valsechi MG, et al. Survival after relapse in children with solid tumors: a follow-up study from the Italian off-therapy registry. Pediatr Blood Cancer. 2006; 6:560-566.
16. Tournade MF, Lemerle J, Brynat-Mentigney M, et al. Ifosfamide is an active drug in Wilms' tumor: a phase II study conducted by the French Society of Pediatric Oncology. J Clin Oncol. 1988;6:793-796.
17. Pinkerton CR, Groot-Loonen J, Morris-Jones PH, et al. Response rates in relapsed Wilms' tumor. A need for effective agents. Cancer. 1991;67:567-571.
18. De Camargo B, Melaragno R, Silva NS, et al. Phase II study of carboplatin as a single drug for relapsed Wilms' tumor: experience of the Brazilian Wilms' Tumor Study Group. Med Pediatr Oncol. 1994;22:258-260.
19. Kung FH, Pratt C, Vega R, et al. Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A Pediatric Oncology Group Phase II study. Cancer. 1993;71:1898-1903. (Pubitemid 23067411)
20. Pein F, Pinkerton R, Roumade MF, et al. Etoposide in relapsed or refractory Wilms' tumor: a phase II study by the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group. J Clin Oncol. 1993;11: 1478-1481.
21. Pein F, Tournade MF, Zucker JM, et al. Etoposide and carboplatin: a highly effective combination in relapsed or refractory Wilms' tumor-a phase II study by the French Society of Pediatric Oncology. J Clin Oncol. 1994;12:931-936.
22. Abu-Ghosh AM, Krailo M, Goldman SC, et al. Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: a Children's Cancer Group report. Ann Oncol. 2002;3:460-469.
23. Metzger ML, Stewart C, Freeman BB, et al. Topotecan is active against Wilms' tumor: results of a multi-institutional phase II study. J Clin Oncol. 2007;25:3130-3136.
24. Dome JS, Liu T, Krasin M, et al. Improved survival for patients with recurrent Wilms tumor: the experience at St. Jude Children's Research Hospital. J Pediatr Hematol Oncol. 2002;24:192-198.
25. Pein F, Michon J, Valteau X, et al. High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms' tumor: a French Society of Pediatric Oncology study. J Clin Oncol. 1998; 16:3295-3301.
26. Kullendorff CM, Bekassy AN. Salvage treatment of relapsing Wilms' tumour by autologous bone marrow transplantation. Eur J Pediatr Surg. 1997;7:177-179.
27. Spreafico F, Bisogno GC, Collini P, et al. Treatment of high-risk relapsed Wilms tumor with dose-intensive chemotherapy, marrow-ablative chemotherapy, and autologous hematopoietic stem cell support: experience by the Italian Association of Pediatric Hematology and Oncology. Pediatr Blood Cancer. 2008;51:23-28.
28. Malogolowkin M, Cotton C, Green D, et al. Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group. Pediatr Blood Cancer. 2008; 50:236-241.
29. Green DM, Cotton C, Malogoloowkin M, et al. Treatment of Wilms tumor relapsing after initial Mreatment with vincristine and actinomycin D: a report from the National Wilms Tumor Study Group. Pediatr Blood Cancer. 2007;8:493-499.